Survey of Ophthalmology
Volume 47, Supplement 1 , Pages S65-S76, August 2002

The Effect of Latanoprost on Intraocular Pressure During 2 Years of Treatment☆

  • Katarina Hedman, MSc

      Affiliations

    • Corresponding Author InformationReprint address: Katarina Hedman, UF35-2, Pharmacia Diagnostics, S-751 82 Uppsala, Sweden
    • Department of Neuro Science Ophthalmology, University Hospital, Uppsala, Sweden
    • Pharmacia Diagnostics, Uppsala, Sweden
    • ,
  • Peter G. Watson, FRCS

      Affiliations

    • Addenbrooke's Hospital, Cambridge, United Kingdom
    • ,
  • Albert Alm, MD

      Affiliations

    • Department of Neuro Science Ophthalmology, University Hospital, Uppsala, Sweden

Abstract 

Our objective was to study the intraocular pressure (IOP) in open-angle glaucoma or ocular hypertensive patients during long-term treatment with latanoprost. A total of 532 patients treated with 0.005% latanoprost were enrolled, including 493 and 113 patients treated for 6 and 24 months, respectively. Mean IOP was analyzed with the analysis of variance technique. The risk of treatment failure was analyzed with survival analysis technique. After 2 weeks of latanoprost treatment, the mean IOP was reduced 8.2 (32%) and 8.9 (34%) mm Hg in the subgroups of patients treated for 6 and 24 months, respectively. The change in mean IOP during 2 years of latanoprost treatment was not statistically significant (p = 0.15). Patients with primary open-angle glaucoma or ocular hypertension showed an 86% and 97% chance of receiving a sufficient IOP reduction with latanoprost (p < 0.01), repectively. The initial mean IOP reduction was maintained throughout the 2 years of treatment.

Keywords:  intraocular pressure, latanoprost, ocular hypertension, open-angle glaucoma, prostaglandin, timolol

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Supported by Pharmacia Corporation, Peapack, New Jersey, USA. Dr. Alm is a consultant to Pharmacia Corporation, Stockholm, Sweden. Katarina Hedman is employed by Pharmacia Diagnostics, Uppsala, Sweden. None of the authors reported any proprietary interest in the development or marketing of drugs used in the clinical trials subject to the pooled data analysis. The authors thank Adam Taube, PhD, Department of Information Science—Statistics, Uppsala University, Uppsala, Sweden.

PII: S0039-6257(02)00301-6

Survey of Ophthalmology
Volume 47, Supplement 1 , Pages S65-S76, August 2002

Article Tools

* Image Usage & Resolution